Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor purchased 14,500 shares of the firm's stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average price of $3.78 per share, with a total value of $54,810.00. Following the purchase, the chief executive officer now owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Perspective Therapeutics Stock Up 18.4 %
Shares of CATX opened at $4.37 on Wednesday. The company has a 50-day moving average of $11.15. Perspective Therapeutics, Inc. has a 52-week low of $2.28 and a 52-week high of $19.05.
Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, equities research analysts forecast that Perspective Therapeutics, Inc. will post -0.86 EPS for the current fiscal year.
Analyst Ratings Changes
Trump won. Buy this coin now.
From Weiss Ratings | Ad
Juan Villaverde called the top and bottom of every crypto bull market since 2012.
He believes Bitcoin will go to $150,000 — or more.
But there’s one coin he thinks could go even higher.
This could be his favorite coin.
CATX has been the subject of a number of analyst reports. Wedbush restated an "outperform" rating and set a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Cantor Fitzgerald restated an "overweight" rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a "buy" rating and a $21.00 price objective for the company. Oppenheimer cut their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, November 22nd. Finally, UBS Group initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $20.00 price objective for the company. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $15.14.
Check Out Our Latest Analysis on CATX
Institutional Investors Weigh In On Perspective Therapeutics
Large investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $57,000. US Bancorp DE grew its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $152,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $153,000. 54.66% of the stock is owned by institutional investors and hedge funds.
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
